Extended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib

Extended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib

Bibliographic Details
Main Authors:	Ali, Siraj M., He, Je, Carson, Wade, Stephens, Phil J., Fiorillo, Joseph, Lipson, Doron, Palmer, Gary A., Ross, Jeffrey S., Miller, Vincent A., Sharman, Jeffrey
Format:	Online
Language:	English
Published:	S. Karger AG 2014
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4067722/

Similar Items

Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma
by: Fisher, Rosalie, et al.
Published: (2012)

Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor
by: Aylwin, Simon J. B., et al.
Published: (2015)

Development of potent autophagy inhibitors that sensitize oncogenic BRAF V600E mutant melanoma tumor cells to vemurafenib
by: Goodall, Megan L, et al.
Published: (2014)

Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma
by: HE, GUOPING, et al.
Published: (2014)

Long Term Survival and Continued Complete Response of Vemurafenib in a Metastatic Melanoma Patient with BRAF V600K Mutation
by: Sahadudheen, K., et al.
Published: (2016)

Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib
by: Nowara, Elzbieta, et al.
Published: (2016)

Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas
by: Sponghini, Andrea P, et al.
Published: (2015)

Comparison of Testing Methods for the Detection of BRAF V600E Mutations in Malignant Melanoma: Pre-Approval Validation Study of the Companion Diagnostic Test for Vemurafenib
by: Lopez-Rios, Fernando, et al.
Published: (2013)

Differential Inhibition of Ex-Vivo Tumor Kinase Activity by Vemurafenib in BRAF(V600E) and BRAF Wild-Type Metastatic Malignant Melanoma
by: Tahiri, Andliena, et al.
Published: (2013)

BRAF in Papillary Thyroid Carcinoma
by: Lanzilotta, Salvatore Giovanni, et al.
Published: (2007)

Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model
by: Danysh, Brian P., et al.
Published: (2016)

Shifted termination assay (STA) fragment analysis to detect BRAF V600 mutations in papillary thyroid carcinomas
by: Kang, So Young, et al.
Published: (2013)

Clinical and histopathological profile of BRAF V600E mutation in conventional papillary thyroid carcinoma in a Filipino population
by: Nur Asiha Binti Sazali
Published: (2016)

BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients
by: Sun, Jian, et al.
Published: (2016)

Vemurafenib enhances MHC induction in BRAFV600E homozygous melanoma cells
by: Sapkota, Bishu, et al.
Published: (2013)

Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent
by: del Bufalo, Francesca, et al.
Published: (2014)

First-Line Use of Vemurafenib to Enable Thyroidectomy and Radioactive Iodine Ablation for BRAF-Positive Metastatic Papillary Thyroid Carcinoma: A Case Report
by: Dao, Bao D., et al.
Published: (2015)

A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma
by: Joseph I. Clark, et al.
Published: (2018-07-01)

Vemurafenib in Chinese patients with BRAF V600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study
by: Lu Si, et al.
Published: (2018-05-01)

Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting
by: Gibney, Geoffrey T, et al.
Published: (2015)

Vemurafenib: First-in-Class BRAF-Mutated Inhibitor for the Treatment of Unresectable or Metastatic Melanoma
by: Shelledy, Lindsay, et al.
Published: (2015)

Dupuytren’s contractures associated with the BRAF inhibitor vemurafenib: a case report
by: Chan, Sze Wai, et al.
Published: (2015)

Corticosteroids Augment BRAF Inhibitor Vemurafenib Induced Lymphopenia and Risk of Infection
by: Sondermann, Wiebke, et al.
Published: (2015)

Trametinib with or without Vemurafenib in BRAF Mutated Non-Small Cell Lung Cancer
by: Joshi, Monika, et al.
Published: (2015)

T cell therapy in combination with Vemurafenib in BRAF mutated metastatic melanoma patients
by: Borch, Troels Holz, et al.
Published: (2014)

Somatic V600E BRAF mutation in linear and sporadic syringocystadenoma papilliferum
by: Levinsohn, Jonathan L., et al.
Published: (2015)

The Utility of BRAF Testing in the Management of Papillary Thyroid Cancer
by: Melck, Adrienne L., et al.
Published: (2010)

BRAF Testing in Multifocal Papillary Thyroid Carcinoma
by: Kimbrell, Hillary Z., et al.
Published: (2015)

BRAF V600E mutations are characteristic for papillary craniopharyngioma and may coexist with CTNNB1-mutated adamantinomatous craniopharyngioma
by: Larkin, Sarah Jane, et al.
Published: (2014)

The role of BRAF V600 mutation in melanoma
by: Ascierto, Paolo A, et al.
Published: (2012)

A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy
by: Williams, Casey B, et al.
Published: (2015)

BRAF mutation is not predictive of long-term outcome in papillary thyroid carcinoma
by: Henke, Lauren E, et al.
Published: (2015)

S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAFV600E/Mt to Vemurafenib
by: Xuelong Jiao, et al.
Published: (2018-09-01)

Prediction Table and Nomogram as Tools for Diagnosis of Papillary Thyroid Carcinoma: Combined Analysis of Ultrasonography, Fine-Needle Aspiration Biopsy, and BRAF V600E Mutation
by: Kim, Seo Ki, et al.
Published: (2015)

Immunohistochemistry with the anti-BRAF V600E (VE1) antibody: impact of pre-analytical conditions and concordance with DNA sequencing in colorectal and papillary thyroid carcinoma
by: Dvorak, Katerina, et al.
Published: (2014)

Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells
by: Fedorenko, Inna V., et al.
Published: (2015)

A Case of Multifocal Papillary Thyroid Carcinoma Consisting of One Encapsulated Follicular Variant with BRAF K601E Mutation and Three Conventional Types with BRAF V600E Mutation
by: Kim, Wook Youn, et al.
Published: (2013)

Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas
by: Brastianos, Priscilla K., et al.
Published: (2014)

Clinical implication of the BRAFV600E mutation in papillary thyroid carcinoma
by: Kim, Yong-Seok, et al.
Published: (2013)

Vemurafenib-resistant BRAF selects alternative branch points different from its wild-type BRAF in intron 8 for RNA splicing
by: Ajiro, Masahiko, et al.
Published: (2015)